[October 22, 2014]

Opexa Therapeutics Supports National Multiple Sclerosis Society and Walk MS

Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced its partnership with the National Multiple Sclerosis Society, Lone Star Chapter, as a sponsor of the nonprofit's annual Houston area Walk MS fundraisers for the fourth consecutive year.

Opexa is supporting the Walk MS program for the Society's Texas Lone Star Chapter, which serves more than 68,000 individuals affected by MS in Texas. The Houston area fundraisers take place throughout October and November and consist of four local walks, including in The Woodlands, the location of Opexa's corporate headquarters.

"Opexa is proud to be a partner of the National MS Society's Houston area Walk MS events," stated Neil K. Warma, Opexa's President and Chief Executive Officer. "We are committed to helping the Society support critical programs and services to improve the quality of life for people affected by MS. We are dedicated to developing a personalized therapy for Secondary Progressive MS, and these events offer the unique opportunity for those of us in the Company to meet people living with MS and their families, which provides us with tremendous motivation."

Walk MS is the rallying point of the MS Movement, a community coming together to raise funds and celebrate hope for the future for the more than 2.3 million people living with MS worldwide. In 2013, Walk MS events throughout the South Central Chapter territory, which includes The Lone Star Chapter, attracted more than 25,000 participants and raised more than $3.2 million for the National Multiple Sclerosis Society. Nationally, since 1988, Walk MS has raised more than $770 million to support life changing programs and cutting-edge research an development of new therapies.

Opexa would like to remind Walk MS participants that there will be a donation drop-off day for the fundraisers at the Company's offices in The Woodlands on Wednesday, October 22^nd from 11:00 am -1:00 pm CT. Phone (News - Alert) 281-775-0609 for more information.

About Opexa

Opexa is a biopharmaceutical company developing personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on Opexa's proprietary T-cell technology. The Company's leading therapy candidate, Tcelna^®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. Tcelna is derived from T-cells isolated from the patient's peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin. Opexa's mission is to lead the field of Precision Immunotherapy® by aligning the interests of patients, employees and shareholders.

For more information visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Forward-Looking Statements

Statements contained in this release, other than statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words "expects," "believes," "may," "intends," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements do not constitute guarantees of future performance. Investors are cautioned that forward-looking statements, including without limitation statements regarding the safety, efficacy and projected development timeline of drug candidates such as Tcelna^® and OPX-212 constitute forward-looking statements. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include without limitation our ability to raise additional capital to continue our development programs, our ability to successfully develop potential products such as Tcelna, our ability to obtain, maintain and protect intellectual property rights (including for Tcelna and future pipeline candidates such as OPX-212), as well as other risks associated with the process of discovering, developing and commercializing drug candidates that are safe and effective for use as human therapeutics. These and other risks are described in detail in our SEC (News - Alert) filings, including our Annual Report on Form 10-K for the year ended December 31, 2013 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2014. All forward-looking statements contained in this release speak only as of the date on which they were first made by us, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after such date.

[ Back To TMCnet.com's Homepage ]